Contact us

Eurobio Oncology

EndoPredict®: Result Report

Understanding the EndoPredict® Report

The EndoPredict test report delivers clear, clinically actionable insights to help guide treatment decisions in early-stage ER-positive/HER2-negative breast cancer. By combining molecular data from the 12-Gene Molecular Score with clinical factors like tumor size and lymph node status, the report provides the comprehensive EPclin Risk Score – a powerful tool for determining an individual patient’s risk of distant recurrence and chemotherapy benefit.1,2,3

  • The Report Answers Three Key Questions:
  • What is the 10-year risk of distant recurrence?1
  • Is adjuvant chemotherapy likely to benefit this patient?2
  • Can extended endocrine therapy be avoided based on the late (5–15 year) risk?3

EndoPredict is a second-generation genomic test with a well-established and reliable cut-off between low- and high-risk groups – ensuring consistent interpretation over time.1 The results are delivered quickly, and the report format is intuitive, helping clinicians make confident, individualized decisions together with their patients.

Test access & ordering

Fast, Clear, and Actionable: The EndoPredict® Result Report

Click below to see an example report and what each page tells you.

Summary Dashboard All Information at a Glance
10 Year Risk of Recurrence Can Chemotherapy be Avoided?
Chemotherapy Benefit How Beneficial would Chemotherapy be?
5-15 Year Risk Can Endocrine Therapy be Stopped After 5 Years?

Reliable Testing on Core Biopsy Tissue

Faster Results from Diagnostic Biopsy - No Need to Wait for Surgery

EndoPredict can be performed on diagnostic biopsy samples – as soon as the indication is confirmed clinically. Studies show a high correlation between results from core biopsies and surgical specimens, ensuring accurate risk assessment early in the treatment journey.4

Before pathological tumor size and nodal status are known, an initial Summary Report based on the 12-Gene Molecular Score will be be generated.

EndoPredict® Testing – Fast, Local, Reliable

The EndoPredict prognostic and predictive breast cancer test is performed in certified local laboratories, with results typically available within just a few days.

Physicians can conveniently order EndoPredict through a wide network of participating labs.

Use the link below to find participating labs and place your order.
Have questions? Feel free to contact us.

Test access & ordering
Contact Us
  1. Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin. Cancer Res. 2011
  1. Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019
  1. Filipits M. et al.: Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019
  1. Müller B. M. et al.: Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections. J Clin Pathol. 2012

Search

en_GB
en_GB fr_FR it_IT es_ES de_DE
Scroll to Top
Summary Dashboard - All Information at a Glance1,2,3

The report lists the 12-Gene

Molecular Score, tumor size,

and nodal status - these are combined

to calculate the final EPclin Risk Score.1

Color-coded

Green = low risk

Blue = high risk

Three key clinical

answers, aligned with treatment

planning stages

Clear Classification into Low or

High EPclin Risk1
The EPclin Score

ranges from 1.0 to 6.0.

- A score of 3.3 or lower

indicates a low risk of recurrence

(less than 10%).

-A score of 3.4 or higher

indicates a high risk of recurrence

(10% or more).

This clear cut-off enables confident

decision-making in clinical practice.

Risk of distant recurrence

in years 0-101

Absolute benefit

from chemotherapy2

Risk of late recurrence

in years 5-153

The EndoPredict report supports physicians in explaining how molecular biology and clinical pathology together determine individual risk.

The final result- the EPclin Risk Score – combines the 12-Gene Molecular Score with key clinical factors (tumor size and nodal status) to provide a precise risk of distant recurrence and estimate the benefit of chemotherapy for each patient.

Download PDF
10 Year Risk of Recurrence – Can Chemotherapy be Avoided?1

EPclin Risk Score

and Risk Class​

The curve ​
illustrates how the risk
of distant recurrence
changes for each
EPclin Risk Score. The
patient’s individual risk
is marked directly on
the curve for easy
interpretation.​

Patient`s individual risk

of distant recurrence

within years 0-101​

Visualizing Risk to Support Shared Decisions​
The clear, easy-to-understand graphic showing 10-year recurrence risk helps guide conversations with patients.​

​It supports discussions about whether to pursue more aggressive treatment or confidently avoid chemotherapy based on the known risk.​

​

 
Download PDF
Chemotherapy Benefit – How Beneficial would Chemotherapy be?2

EPclin Risk Score

and Risk Class​

The graph displays two
curves: one
from patients with
chemotherapy and one
without. The difference
between them
represents the patient’s
absolute benefit from
chemotherapy, based
on their EPclin Risk Score.​

Patient`s 10-year
Chemotherapy Benefit2

Clear Visualization of Individual Chemotherapy Benefit​
The graphic makes it easy to explain the absolute benefit of chemotherapy, helping physicians and patients make informed, personalized treatment decisions.​

 
Download PDF

Chemotherapy Benefit – How Beneficial would Chemotherapy be?2

EPclin Risk Score

and Risk Class​

The curve displays
distant recurrence
risk over years 5 to
15 for each EPclin Risk
Score, with the
patient’s individual
risk clearly marked.​

Patient`s Individual risk of 
distant recurrence within in
years 5-153

Long-Term Risk Visualization to Support Endocrine Therapy Decisions​
This graph illustrates the individual risk of recurrence between years 5 and 15 after diagnosis, helping guide discussions about the potential need for extended endocrine therapy.​

​

 
Download PDF

Summary Report from Diagnostic Biopsy​

EPclin Score and Risk
Classification
available once pT and
pN are confirmed​

Based on the patient’s
molecular score, the
table displays the 10-
year risk of distant
recurrence and the
potential chemotherapy
benefit, adjusted
according to different
nodal statuses and
tumor sizes.​

12-Gene Molecular
Score​

When pathological tumor size and nodal status are not yet available, EndoPredict provides an interim report based on the 12-Gene Molecular Score. This preview helps estimate the impact of clinical factors on the final Epclin Risk Score result. ​

Once pT and pN status are available post-surgery, the full report can be completed directly in your pathology lab – reducing delays in treatment planning and easing patient anxiety.​

Download PDF